|
[(3R,6S)-6-甲基哌啶-3-基]甲醇盐酸盐
|
R171459-100mg
|
≥97% |
N/A |
100mg
|
¥ 4203.9
|
期货,请咨询 |
|
0 |
阿拉丁 |
|
醋酸[(1R,2R)-rel-2-(羟甲基)环丁基]甲基丙烯酸甲酯
|
R171458-1g
|
≥97% |
N/A |
1g
|
¥ 36.9
|
期货,请咨询 |
|
0 |
阿拉丁 |
|
(5R)-1-[(叔丁氧基)羰基] -5-甲基吡咯烷-3-羧酸
|
R171455-1g
|
≥97% |
N/A |
1g
|
¥ 36.9
|
期货,请咨询 |
|
0 |
阿拉丁 |
|
(3R)-1-甲基吡咯烷-3-羧酸盐酸盐
|
R171453-1g
|
≥97% |
N/A |
1g
|
¥ 36.9
|
期货,请咨询 |
|
0 |
阿拉丁 |
|
(2R,6R)-1,2,6-三甲基哌嗪二盐酸盐
|
R171451-500mg
|
≥97% |
N/A |
500mg
|
¥ 20137.9
|
期货,请咨询 |
|
0 |
阿拉丁 |
|
(1R,3R)-3-氨基环己烷-1-羧酸盐酸盐
|
R171449-250mg
|
≥97% |
N/A |
250mg
|
¥ 8755.9
|
期货,请咨询 |
|
0 |
阿拉丁 |
|
[117491-83-5]ROX-N-羟基琥珀酰亚胺酯,纯6-异构体
|
R171432-100mg
|
|
117491-83-5 |
100mg
|
¥ 13483.9
|
期货,请咨询 |
|
0 |
阿拉丁 |
|
[117491-83-5]ROX-N-羟基琥珀酰亚胺酯,纯6-异构体
|
R171432-50mg
|
|
117491-83-5 |
50mg
|
¥ 7875.9
|
期货,请咨询 |
|
0 |
阿拉丁 |
|
[117491-83-5]ROX-N-羟基琥珀酰亚胺酯,纯6-异构体
|
R171432-25mg
|
|
117491-83-5 |
25mg
|
¥ 4646.9
|
期货,请咨询 |
|
0 |
阿拉丁 |
|
[117491-83-5]ROX-N-羟基琥珀酰亚胺酯,纯6-异构体
|
R171432-5mg
|
|
117491-83-5 |
5mg
|
¥ 2380.9
|
期货,请咨询 |
|
0 |
阿拉丁 |
|
[117491-83-5]ROX-N-羟基琥珀酰亚胺酯,纯6-异构体
|
R171432-1mg
|
|
117491-83-5 |
1mg
|
¥ 1247.9
|
期货,请咨询 |
|
0 |
阿拉丁 |
|
ROX 叠氮化物,5-异构体,10 mM/DMSO
|
R171384-1ml
|
|
N/A |
1ml
|
¥ 4646.9
|
期货,请咨询 |
|
0 |
阿拉丁 |
|
ROX炔烃,5-异构体
|
R171382-100mg
|
|
N/A |
100mg
|
¥ 13483.9
|
期货,请咨询 |
|
0 |
阿拉丁 |
|
ROX炔烃,5-异构体
|
R171382-50mg
|
|
N/A |
50mg
|
¥ 7875.9
|
期货,请咨询 |
|
0 |
阿拉丁 |
|
ROX炔烃,5-异构体
|
R171382-25mg
|
|
N/A |
25mg
|
¥ 4646.9
|
期货,请咨询 |
|
0 |
阿拉丁 |
|
ROX炔烃,5-异构体
|
R171382-10mg
|
|
N/A |
10mg
|
¥ 3513.9
|
期货,请咨询 |
|
0 |
阿拉丁 |
|
ROX炔烃,5-异构体
|
R171382-5mg
|
|
N/A |
5mg
|
¥ 2380.9
|
期货,请咨询 |
|
0 |
阿拉丁 |
|
ROX炔烃,5-异构体
|
R171382-1mg
|
|
N/A |
1mg
|
¥ 1247.9
|
期货,请咨询 |
|
0 |
阿拉丁 |
|
Razaxaban盐酸盐
|
R170194-25mg
|
≥98%(HPLC) |
405940-76-3 |
25mg
|
¥ 4051.9
|
期货,请咨询 |
|
0 |
阿拉丁 |
|
Razaxaban盐酸盐
|
R170194-5mg
|
≥98%(HPLC) |
405940-76-3 |
5mg
|
¥ 1005.9
|
期货,请咨询 |
|
0 |
阿拉丁 |
|
R(+)-维拉帕米单盐酸盐
|
R170035-25mg
|
≥95% |
38176-02-2 |
25mg
|
¥ 7825.9
|
期货,请咨询 |
|
0 |
阿拉丁 |
|
R(+)-维拉帕米单盐酸盐
|
R170035-5mg
|
≥95% |
38176-02-2 |
5mg
|
¥ 1772.9
|
期货,请咨询 |
|
0 |
阿拉丁 |
|
(R)-(+)-5,5-二苯基-4-异丁基-2-恶唑烷酮
|
R169835-500mg
|
|
352535-72-9 |
500mg
|
¥ 1227.9
|
期货,请咨询 |
|
0 |
阿拉丁 |
|
RS504393,CCR2趋化因子受体拮抗剂
|
R169388-25mg
|
Moligand™, ≥98%(HPLC) |
300816-15-3 |
25mg
|
¥ 3214.9
|
现货 |
|
0 |
阿拉丁 |